Skip to main content

Table 1 Basic clinical characteristics of patients in the TCGA cohort and CPTAC Cohort

From: A novel ferroptosis-related gene signature associated with cell cycle for prognosis prediction in patients with clear cell renal cell carcinoma

 

TCGA Cohort (531)

CPTAC Cohort (98)

Age(years)

 ≥65

198(37.3%)

41(41.8%)

 <65

333(62.7%)

57(58.2%)

Sex

 Male

345(65.0%)

75(76.5%)

 Female

186(35.0%)

23(23.5%)

Grade

 G1

13(2.4%)

6(6.1%)

 G2

229(43.1%)

47(48.0%)

 G3

205(38.6%)

36(36.7%)

 G4

76(14.3%)

9(9.2%)

 Unknown

8(1.5%)

0

Stage

 I

266(50.1%)

46(46.9%)

 II

57(10.7%)

11(11.2%)

 III

124(23.4%)

31(31.6%)

 IV

84(15.8%)

10(10.2%)

T stage

 T1

271(51.0%)

48(49.0%)

 T2

69(13.0%)

12(12.2%)

 T3

180(33.9%)

37(37.8%)

 T4

11(2.1%)

1(1.0%)

N stage

 N1

16(3.0%)

/

 N0

240(45.2%)

/

 Unknown

275(51.8%)

/

M stage

 M1

79(14.9%)

/

 M0

422(79.5%)

/

 Unknown

30(5.6%)

/

Survival

 Dead

175(33.0%)

12(12.2%)

 Living

356(67.0%)

86(87.8%)